Shares of Argenx SE (NASDAQ: ARGX) surged over 9% in pre-market trading on Wednesday after the biopharmaceutical company reported stellar third quarter 2024 financial results that trounced analysts' estimates.
For the quarter ended September 30, Argenx posted earnings per share of $1.39, obliterating the consensus estimate of just $0.02. The company's revenue of $588.9 million also surpassed expectations, coming in 9.35% higher than the $538.5 million analysts had forecast.
The blockbuster Q3 results marked a sharp turnaround from the year-ago period when Argenx lost $1.25 per share. Sales skyrocketed 73% year-over-year as well, underscoring the remarkable growth trajectory the biotech firm is on.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.